Humana (HUM) Stock Forecast & Price Target

Q: What analysts cover Humana?

Humana has been rated by research analysts at Barclays , Cantor Fitzgerald , Deutsche Bank Aktiengesellschaft , Evercore , Guggenheim , Jefferies Financial Group , JPMorgan Chase & Co. , Leerink Partners , Mizuho , Morgan Stanley , Needham & Company LLC , Oppenheimer , Piper Sandler , Raymond James Financial , Robert W. Baird , Royal Bank Of Canada , TD Cowen , The Goldman Sachs Group , Truist Financial , UBS Group , Weiss Ratings , Wells Fargo & Company , William Blair , Wolfe Research , and Zacks Research in the past 90 days.

$320.57 -7.74 (-2.36%)

Closing price 03:59 PM Eastern

Extended Trading

$321.00 +0.43 (+0.13%)

As of 06:53 PM Eastern

Compare

Humana - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 28 Analyst Ratings

Sell
4

Hold
15

Buy
9

Based on 28 Wall Street analysts who have issued ratings for Humana in the last 12 months, the stock has a consensus rating of "Hold." Out of the 28 analysts, 4 have given a sell rating, 15 have given a hold rating, and 9 have given a buy rating for HUM.

Consensus Price Target

$272.65
-14.95% Downside

According to the 28 analysts' twelve-month price targets for Humana, the average price target is $272.65. The highest price target for HUM is $441.00, while the lowest price target for HUM is $195.00. The average price target represents a forecasted downside of -14.95% from the current price of $320.57.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for HUM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Humana and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HUM Analyst Ratings Over Time

Type	Current Forecast 6/2/25 to 6/2/26	1 Month Ago 5/3/25 to 5/3/26	3 Months Ago 3/4/25 to 3/4/26	1 Year Ago 6/2/24 to 6/2/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)
Hold	15 Hold rating(s)	15 Hold rating(s)	15 Hold rating(s)	15 Hold rating(s)
Sell	4 Sell rating(s)	4 Sell rating(s)	4 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$272.65	$247.61	$225.48	$284.48
Forecasted Upside	-14.95% Downside	5.88% Upside	22.99% Upside	23.17% Upside
Consensus Rating	Hold	Hold	Hold	Hold

HUM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HUM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Humana Stock vs. The Competition

Type	Humana	Medical Companies	Broader Market
Consensus Rating Score	2.18	2.30	2.52
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	-16.04% Downside	1,730.99% Upside	15.50% Upside
News Sentiment Rating	Positive News See Recent HUM News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
6/1/2026	Royal Bank Of Canada 3 of 5 stars	Ben Hendrix 3 of 5 stars	Reiterated Rating	Sector Perform
6/1/2026	Truist Financial 3 of 5 stars	David MacDonald 2 of 5 stars	Boost Target	Hold	$270.00 ➝ $320.00	-3.32%
5/26/2026	Barclays 3 of 5 stars	Andrew Mok 3 of 5 stars	Boost Target	Equal Weight	$180.00 ➝ $344.00	+12.93%
5/22/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	A.J. Rice Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$262.00 ➝ $320.00	+5.57%
5/20/2026	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Neutral ➝ Overweight
5/20/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Outperform
5/20/2026	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Buy
5/20/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Outperform
5/20/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	George Hill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/20/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Peer Perform
Get the Latest News and Ratings for HUM and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Humana and its competitors with MarketBeat's FREE daily newsletter.
5/20/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Buy
5/20/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Stephen Baxter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Cautious ➝ Reduce
5/20/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ann Hynes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$290.00 ➝ $335.00	+8.12%
5/15/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Erin Wright Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Underweight	$146.00 ➝ $217.00	-27.79%
5/13/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jessica Tassan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral	$182.00 ➝ $254.00	-14.00%
5/13/2026	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong Sell ➝ Hold
5/1/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ryan Langston Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Hold	$173.00 ➝ $211.00	-9.15%
5/1/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform	$260.00	+9.77%
5/1/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lisa Gill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$180.00 ➝ $214.00	-9.56%
4/30/2026	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jason Cassorla Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$252.00 ➝ $269.00	+10.26%
4/30/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target		$195.00 ➝ $250.00	+4.75%
4/30/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Sell	$158.00 ➝ $195.00	-18.29%
4/30/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Market Perform	$185.00 ➝ $255.00	+6.85%
4/21/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Sell (D+)
4/15/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Neutral	$264.00 ➝ $205.00	+4.99%
1/6/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lance Wilkes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$344.00	+24.57%
12/12/2025	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Sector Weight
10/10/2025	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kevin Fischbeck Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$280.00 ➝ $300.00	+5.92%
10/9/2024	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Scott Fidel Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Equal Weight	$250.00 ➝ $250.00	+2.35%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 07:13 PM ET.

Should I Buy Humana Stock? HUM Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, May 31, 2026. Please send any questions or comments about these Humana pros and cons to contact@marketbeat.com.

Humana
Bull Case

Here are some ways that investors could benefit from investing in Humana Inc.:

Humana Inc. has recently seen an upgrade in its stock rating from "strong sell" to "hold," indicating improved sentiment among analysts.
Analysts have raised the target price for Humana Inc. to around $255, suggesting potential upside for investors despite recent market volatility.
The current stock price is approximately $304.95, reflecting a strong market position and investor interest.
Humana Inc. is well-known for its Medicare Advantage plans, which cater to a growing demographic of seniors, providing a stable revenue stream.
The company has a solid market capitalization of about $36.61 billion, indicating its significant presence in the health insurance sector.

Humana
Bear Case

Investors should be bearish about investing in Humana Inc. for these reasons:

Recent earnings estimates for FY2026 and FY2027 have been cut, signaling potential challenges in profitability moving forward.
Concerns have been raised about a projected large loss in Q4 2026, which could negatively impact investor confidence.
Despite a positive rating upgrade, the overall consensus remains a "hold," suggesting caution among analysts regarding future performance.
Humana Inc. has a relatively high PE ratio of 32.62, which may indicate that the stock is overvalued compared to its earnings.
Only a small percentage of the stock is owned by corporate insiders, which may suggest a lack of confidence from those closest to the company.

HUM Forecast - Frequently Asked Questions

According to the research reports of 28 Wall Street equities research analysts, the average twelve-month stock price forecast for Humana is $272.65, with a high forecast of $441.00 and a low forecast of $195.00.

28 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Humana in the last twelve months. There are currently 4 sell ratings, 15 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" HUM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HUM, but not buy additional shares or sell existing shares.

According to analysts, Humana's stock has a predicted downside of -14.95% based on their 12-month stock forecasts.

Over the previous 90 days, Humana's stock had 5 upgrades and 4 downgrades by analysts.

Humana has been rated by research analysts at Barclays, Cantor Fitzgerald, Deutsche Bank Aktiengesellschaft, Evercore, Guggenheim, Jefferies Financial Group, JPMorgan Chase & Co., Leerink Partners, Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer, Piper Sandler, Raymond James Financial, Robert W. Baird, Royal Bank Of Canada, TD Cowen, The Goldman Sachs Group, Truist Financial, UBS Group, Weiss Ratings, Wells Fargo & Company, William Blair, Wolfe Research, and Zacks Research in the past 90 days.

Analysts like Humana less than other "medical" companies. The consensus rating score for Humana is 2.18 while the average consensus rating score for "medical" companies is 2.30. Learn more on how HUM compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Humana Recommendations

This page (NYSE:HUM) was last updated on 6/2/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Humana (HUM) Stock Forecast & Price Target